Form 4: Oruka Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Paul T Quinlan, General Counsel of Oruka Therapeutics, Inc., sold 10,000 shares of common stock on September 21, 2026.
Summary
- Option exercise/conversion: acquired 10,000 Common Stock at $7.80 ($78,000) on September 21, 2026; holds 39,995 after (Direct).
- Open-market sale: disposed of 2,900 Common Stock at $92.37 ($267,870) on September 21, 2026; holds 37,095 after (Direct).
- Open-market sale: disposed of 3,832 Common Stock at $93.32 ($357,592) on September 21, 2026; holds 33,263 after (Direct).
- Open-market sale: disposed of 601 Common Stock at $94.44 ($56,760) on September 21, 2026; holds 32,662 after (Direct).
- Open-market sale: disposed of 2,667 Common Stock at $95.31 ($254,196) on September 21, 2026; holds 29,995 after (Direct).
- Option exercise/conversion: disposed of 10,000 Employee Warrant (right to buy) on September 21, 2026; holds 79,996 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $936,417 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Paul T Quinlan — Officer (General Counsel)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-21 | Option exercise/conversion | Common Stock | 10,000 | $8 | $78.0K | 39,995 |
| 2026-09-21 | Open-market sale | Common Stock | 2,900 | $92 | $267.9K | 37,095 |
| 2026-09-21 | Open-market sale | Common Stock | 3,832 | $93 | $357.6K | 33,263 |
| 2026-09-21 | Open-market sale | Common Stock | 601 | $94 | $56.8K | 32,662 |
| 2026-09-21 | Open-market sale | Common Stock | 2,667 | $95 | $254.2K | 29,995 |
| 2026-09-21 | Option exercise/conversion | Employee Warrant (right to buy) | 10,000 | — | — | 79,996 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-21 | Option exercise/conversion (10,000 shares) |
| 2026-09-21 | Open-market sale (2,900 shares) |
| 2026-09-21 | Open-market sale (3,832 shares) |
| 2026-09-21 | Open-market sale (601 shares) |
| 2026-09-21 | Open-market sale (2,667 shares) |
| 2026-09-21 | Option exercise/conversion (10,000 shares) |
Keywords
insider transaction, Form 4, ORKA, Oruka Therapeutics, Inc., bearish, Paul T Quinlan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.